Gilead Stops Six Clinical Trials For Cancer Medicine Zydelig

The FDA yesterday alerted health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig in combination with other cancer medicines.

Gilead Sciences (GILD) has confirmed that it is stopping six clinical trials in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin lymphomas, the agency said in a statement. The FDA added that it is reviewing the findings of the clinical trials and “will communicate new information as necessary.”